Relmada Therapeutics Charts Aggressive Path After Earnings Call

Relmada Therapeutics Inc ((RLMD)) has held its Q4 earnings call. Read on for the main highlights of the call.

Relmada Therapeutics’ latest earnings call struck an upbeat tone, with management emphasizing what they view as best‑in‑class Phase II efficacy and clean safety for NDV‑01 in non‑muscle invasive bladder cancer alongside clear FDA alignment on a dual‑path Phase III strategy. Rising operating costs, a slightly wider net loss, and competitive pressures were acknowledged, but a strengthened balance sheet and extended cash runway appeared to tilt sentiment firmly positive.

Robust 12‑Month Phase II Efficacy for NDV‑01

NDV‑01 delivered a 76% 12‑month complete response rate in the overall Phase II population and an even stronger 80% 12‑month response in BCG‑unresponsive patients, a particularly hard‑to‑treat group. Complete response at any time reached 95% in the full cohort of 38 patients and 94% in the BCG‑unresponsive subgroup, underpinning management’s confidence in the drug’s potential differentiation.

Clean Safety Profile Supports Best‑in‑Class Ambitions

The company highlighted that no patients in the Phase II study progressed to muscle‑invasive disease, and no radical cystectomies were required, an important safety and quality‑of‑life signal for bladder cancer patients. No grade 3 or higher treatment‑related adverse events, treatment interruptions, or discontinuations were reported, with most side effects limited to grade 1, supporting a favorable risk‑benefit profile.

FDA Alignment and Phase III RESCUE Program Design

Relmada reported securing FDA alignment on a two‑pathway registrational strategy for NDV‑01, covering both intermediate‑risk adjuvant use after TURBT and a second‑line BCG‑unresponsive setting. The company expects U.S. IND clearance and the start of the Phase III RESCUE program in mid‑2026, with around 80 trial sites planned across North America to support robust enrollment and data generation.

Large Addressable Patient Populations Underpin Commercial Upside

Management estimates the U.S. intermediate‑risk post‑TURBT adjuvant market at roughly 70,000–75,000 patients annually, providing a sizable front‑line opportunity if NDV‑01 is approved. The BCG‑unresponsive second‑line segment adds another approximately 5,000 U.S. patients per year, suggesting a meaningful combined revenue potential in a setting where unmet need remains significant.

Financing Extends Cash Runway Through 2029

Relmada closed a $160 million private financing on March 9, 2026, expecting net proceeds of about $150 million on top of $93 million in cash at year‑end 2025. Management believes this strengthened balance sheet will fund operations through 2029, including completion of the planned NDV‑01 Phase III program, reducing near‑term financing risk for investors.

Pipeline Expansion: Cipranolone PoC in Prader‑Willi Syndrome

Beyond oncology, the company is advancing cipranolone, a GABA‑modulating steroid antagonist that has already shown proof‑of‑concept in Tourette syndrome, into rare disease. A proof‑of‑concept Phase II study in Prader‑Willi syndrome is planned to begin in mid‑2026, with ongoing FDA engagement on trial design, signaling a push to diversify the late‑stage pipeline.

Leadership and Scientific Bench Strengthened

Relmada underscored recent organizational upgrades, including the appointment of Dr. Raj S. Pruthi as Chief Medical Officer, Oncology. The company also formed a scientific advisory board composed of leading urologic oncology experts to guide NDV‑01 development, moves intended to sharpen clinical strategy and bolster credibility with regulators and key opinion leaders.

Clear Data Readout Cadence for Investors

Updated 12‑month Phase II NDV‑01 data have been accepted for presentation at an upcoming urology meeting, helping to raise the program’s profile in the specialist community. Looking ahead, Relmada plans to share initial three‑month response data from the Phase III BCG‑unresponsive trial by year‑end 2026 and then provide follow‑ups at roughly three‑month intervals, offering investors a steady stream of clinical catalysts.

Rising G&A and Operating Cash Burn

General and administrative expense climbed to $12.3 million in the fourth quarter of 2025, up from $8.1 million a year earlier, driven largely by higher compensation costs tied to scaling the organization. Net cash used in operating activities also accelerated to $14.6 million from $8.8 million, reflecting increased spend on program start‑ups and operational build‑out as the company prepares for Phase III.

Net Loss Widened Despite Lower R&D Spend

Relmada posted a fourth‑quarter 2025 net loss of $19.9 million, or $0.27 per share, compared with a $18.7 million loss, or $0.06 per share, in the prior‑year period, a modest 6.4% increase in the bottom‑line deficit. Research and development expense actually declined to $8.1 million from $11.0 million, mainly due to winding down two Phase III trials for REL‑1017, partially offset by start‑up spending on NDV‑01 and cipranolone.

Crowded NMIBC Field and Data Limitations Pose Risks

Management acknowledged that non‑muscle invasive bladder cancer is an increasingly crowded arena, with multiple active trials and recent approvals that could pressure both trial enrollment and future market share. They also cautioned that some Phase II subgroup analyses, such as results in patients with carcinoma in situ, rely on small patient numbers and that the absence of a defined FDA durability threshold adds regulatory uncertainty.

Market Education Needed for Intermediate‑Risk Adoption

Only about 35% of intermediate‑risk NMIBC patients currently receive adjuvant therapy, suggesting that even a strong product may face inertia in clinical practice. Relmada expects that commercial success for NDV‑01 in this setting will require targeted physician and patient education to expand use, though the in‑office, sustained‑release profile could help encourage broader adoption over time.

Forward‑Looking Guidance and Key Milestones

Looking ahead, the company plans to initiate the Phase III RESCUE program for NDV‑01 in mid‑2026 at around 80 sites, with one randomized adjuvant intermediate‑risk study targeting a two‑year recurrence‑free survival of roughly 75% and an event‑driven design centered on about 128 events. A single‑arm BCG‑unresponsive study using complete response at any time as the primary endpoint is expected to yield initial three‑month data by the end of 2026, while the cipranolone Prader‑Willi proof‑of‑concept trial is also slated to begin in mid‑2026, all supported by a cash runway projected through 2029.

Relmada’s earnings call painted a picture of a company transitioning from early‑stage development to registrational execution on the back of encouraging NDV‑01 data and substantial new capital. While rising costs, a modestly higher net loss, and a competitive NMIBC landscape remain watch points, investors were left with a clear roadmap of clinical milestones and a balance sheet positioned to pursue what management views as a best‑in‑class opportunity in bladder cancer.